Form 4: Maria Fardis, CRISPR Therapeutics Director, Reports Stock Option Grant

Director Maria Fardis reports the acquisition of stock options for 13,000 common shares of CRISPR Therapeutics AG.

Summary

• Maria Fardis, a director of CRISPR Therapeutics AG, filed a Form 4 on May 31, 2024, reporting a transaction.
• On May 30, 2024, Fardis acquired stock options for 13,000 common shares at an exercise price of $54.06.
• These options vest in 12 equal monthly installments starting May 31, 2024, with the final installment vesting no later than the 2025 Annual General Meeting of Shareholders or the one-year anniversary of the grant date.
• Following the transaction, Fardis directly owns options for 13,000 common shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The sentiment is neutral to positive.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The director's holdings will increase as the options vest over the next year, aligning her interests with the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in biotech companies like CRISPR Therapeutics.
• Companies such as Intellia Therapeutics and Editas Medicine also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of 12 months is typical for these types of grants, aligning with industry norms.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Next Steps

• The director will continue to vest in the stock options over the next 12 months.
• The director may exercise the options in the future, depending on the stock price and personal financial considerations.

Key Dates